Close

Shockwave Medical (SWAV) Announces Maria Sainz to Board

July 20, 2020 8:04 AM EDT

Shockwave Medical, Inc. (NASDAQ: SWAV) announced today that Maria Sainz has joined its Board of Directors and will serve on Shockwave’s Compensation Committee.

“I am delighted to welcome Maria to our Board of Directors,” said Doug Godshall, President and Chief Executive Officer of Shockwave Medical. “Her rich experience in company building and commercialization success within the medical technology sector will make Maria an excellent addition and invaluable strategic resource to Shockwave as we continue to build and grow the company.”

Ms. Sainz, who has over 25 years of experience in leadership and commercial positions in the medical technology industry, currently serves as Chief Executive Officer of Aegea Medical, Inc. Prior to this position, she served as the President and CEO of Cardiokinetix, a medical device company pioneering a catheter-based treatment for heart failure and as the President and CEO of Concentric Medical, Inc., a developer of minimally invasive products for the treatment of acute ischemic stroke, which was acquired in 2011 by Stryker Corporation. Maria began her medical technology career at Guidant Corporation where she held positions of increasing responsibility in Europe and the United States, culminating in her position as President of the Cardiac Surgery division at the time of the acquisition of Guidant Corporation by Boston Scientific. Ms. Sainz has been intimately involved in the launches of several significant medical technology products including coronary stents and cardiac resynchronization therapy devices. She also serves as a member of the board of directors of Orthofix Medical, Inc. and Avanos Medical, Inc. Ms. Sainz received a Master of Arts in Languages from the University Complutense in Madrid, Spain and a Masters in International Management from the American Graduate School of International Management.

“I am honored to join the Shockwave Medical Board of Directors,” said Ms. Sainz. “Shockwave has made tremendous progress transforming the treatment of calcified coronary disease and I am excited to join this esteemed group and to together collaborate with the exceptional management team as Shockwave continues to expand their business, commercial footprint and overall success.”



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Management Changes, Management Comments

Related Entities

Earnings, Definitive Agreement